Vanoxerine

• 67469-69-6
• 67469-78-7 ( dihydrochloride)

Dopamine re -uptake inhibitors

Template: Infobox chemical / molecular formula search available

Vanoxerin, also known under the name of GBR - 12909, is a piperazine derivative that acts in humans as a selective dopamine reuptake inhibitor ( SDRI ). It was developed as a substitute for the treatment of cocaine addicts to mitigate the psychological withdrawal symptoms. GBR - 12909 binds this as cocaine the dopamine reuptake transporter, but without to have 500 times more potent a significant stimulatory effect, since, in contrast to cocaine inhibits the simultaneous release of dopamine. The half-life of Vanoxerin is substantially longer than cocaine.

Since 2006 Vanoxerin is in the second phase, ie, attempts to humans.

There was also an esterified capric acid of Vanoxerin developed (DBL -583 ), which can be given as a depot injection and is effective for about a month.